Drug intelligence / Profile preview

MCS-5

Development stage: Discontinued
Modality: Small Molecules

Overview

MCS-5 is a small molecule drug that was developed for the treatment of male infertility. The drug appears to be derived from the optimization of an aptamer sequence (MCs-12), where its stem-loop structure was cleaved and optimized by sequential removal of bases. Its precise mechanism of action, molecular target, and detailed pharmacological properties are not publicly disclosed. Clinical development reached Phase 2 in Taiwan for male infertility but has since been discontinued[1].

Beyond the preview

Go deeper on MCS-5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCS-5.

Explore the full profile